ShangPharma to Attend Upcoming Investor Conferences in October

Sep 30, 2011, 07:00 ET from ShangPharma Corporation

SHANGHAI, Sept. 30, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its senior management will be participating in the following upcoming conferences in October 2011:

Mr. Kevin Chen, Chief Operating Officer of ShangPharma; Mr. William Dai, Chief Financial Officer; and Ms. Lan Xie, Vice President of Finance and Investor Relations, will be presenting at the following conference in Macau:

  • Citi Greater China Investor Conference October 19-20, 2011 Macau, PRC

Mr. William Dai, Chief Financial Officer of ShangPharma, will be presenting at the following conferences in Beijing:

  • Goldman Sachs China Investment Frontier Conference October 27-28, 2011 Beijing, PRC
  • Bank of America Merrill Lynch New China Conference October 31-November 4, 2011 Beijing, PRC

Presentation materials will be available under the Webcasts & Presentations section of the Company's investor relations website at Investors interested in meeting with ShangPharma during any of the above conferences should contact the relevant institutional sales representatives.

About ShangPharma Corporation  

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit

For further information, please contact:

ShangPharma Corporation

In Shanghai, China

Ms. Lan Xie

VP of Finance and Investor Relations



In New York:

Kimberly Minarovich

Tel: +1 917-533-3268


In Hong Kong:

Tip Fleming

Tel: +852-9212-0684


SOURCE ShangPharma Corporation